Joule, LS9 and Novomer Named to the Global Cleantech 100 2012
Joule, LS9 and Novomer Named to the Global Cleantech 100 2012
Welcome to the Global Cleantech 100 2012
The Global Cleantech 100 represents innovation and highlights the companies most likely to make a significant market impact in the next 5-10 years
The OCS™ Lung Initial European Clinical Experience Featured in The Lancet
The OCS™ Lung Initial European Clinical Experience Featured in The Lancet
Andover, Mass., October 10, 2012, The Lancet has published the initial series of successful lung transplants demonstrating the feasibility and safety of using the Organ
Keraflex® Keratoconus Treatment Study Begins in US
Keraflex® Keratoconus Treatment Study Begins in US
Hersh Vision Group is the first to offer this novel keratoconus treatment
Life Sciences Venture Funding Drops
Life Sciences Venture Funding Drops
In today’s economy, capital is much more difficult to raise, and the various sources of investment, from private angels to larger VC firms, are understandably much more cautious and conservative about where they place their money. “The economic recession made its impact on life sciences investments, as there have been negative returns on investments for the last 12 years.
LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools
LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools
The South San Francisco company LS9 recently produced five tons of industrial chemicals from plant sugars at a Florida demonstration facility, a step toward proving that its genetically engineered microbes can manufacture carbon compounds and fuels at a commercial scale.
T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012
T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012
LEXINGTON, Mass., Oct 02, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012.
Shire scoops up Pervasis Therapeutics
The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States
The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States
Acceleron one of only two biopharmaceutical companies to make the list
Flagship Ventures CEO keeps Merck aboard to inform biotech bets
Flagship Ventures CEO keeps Merck aboard to inform biotech bets
Largely gone are the days when venture capitalists could hatch a biotech and take it public without much regard for the needs of Big Pharma. Public investors seldom buy into new biotech companies, and drugmakers have increasingly become early partners with VC firms and their young ventures. In the process, pharma has gained significant clout in the biotech VC game.



